ClinicalTrials.gg
CompletedNCT06273540Updated Nov 18, 2026

Phase1, STP7 Cocaine Drug-Drug Interaction Study

A Phase 1 interventional study of STP7 (mavoglurant) and Placebo in Cocaine Use Disorder, sponsored by Stalicla SA. Completed at 1 site in United States. Open to participants aged 18 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Stalicla SA · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Oct 2024, 2 years 1 month ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Oct 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years to 59 Years
Sex
All
01

Study summary

This is a double-blind, placebo-controlled, parallel group study to compare the effects of STP7 (mavoglurant) vs placebo control on i.v. cocaine's physiological and subjective effects in non-treatment seeking, cocaine-experienced males or females participants between 18 and 59 years of age.

The primary objective of this study is to determine if there are clinically meaningful interactions between oral STP7 (mavoglurant) treatment concurrent with 20 and 40 mg i.v. cocaine infusions by measuring adverse events and cardiovascular responses including heart rate, blood pressure, and electrocardiogram (including corrected QT interval).

The secondary objectives are:

  • To evaluate whether administration of STP7 (mavoglurant) alters the pharmacokinetics of cocaine and/or its major metabolite, benzoylecgonine.
  • To determine the pharmacokinetic of STP7 (mavoglurant) administered at a dose of 200 mg twice a day.
  • To evaluate whether STP7 (mavoglurant) treatment alters the subjective effects of cocaine measured by Visual Analog Scales (VAS) and Brief Substance Craving Scale (BSCS).
02

Conditions studied

  • Cocaine Use Disorder

Keywords

  • STP7
  • mavoglurant
  • Cocaine
  • AFQ056
  • metabotropic glutamate receptor 5
  • mGluR5
  • CUD
03

In context

Lead sponsor

Stalicla SA is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be participants who are cocaine-experienced and not seeking treatment for cocaine use disorder.
  2. Males and females between 18 and 59 years of age, inclusive.
  3. Have a (BMI) within a range of 17.0 to 36.0 kg/m2 and a minimum weight of at least 50.0 kg at screening.
  4. Have experience using cocaine by the smoked or i.v. route at least 6 times in the past 12 months prior to clinic intake (Day -3) and at least one use (smoked, i.v., or nasal route) within the past 3 months.
  5. Provide a urine sample positive for cocaine at least once during screening (Days -28 to -4).
  6. Be able to verbalize understanding of consent form, able to provide written , and verbalize willingness to complete study procedures.
  7. A female study participant must meet one of the following criteria:

    If of - agrees to use one of the accepted regimens from at least 30 days prior to the first administration of the study medication, during the study, and for at least 30 days after the last dose of the study medication. An acceptable method of contraception includes one of the following:

    i. Abstinence from heterosexual intercourse ii. Hormonal contraceptives (injectable/implant/insertable hormonal birth control products, transdermal patch) iii. Intrauterine device (with or without hormones) OR agrees to use a double barrier method (e.g. condom and spermicide) during the study and for at least 30 days after the last dose of the study medication. If a female of non-childbearing potential - should be surgically sterile (i.e. has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation/occlusion) or in a menopausal state (at least 1 year without menses), as confirmed by FSH levels.

    A male study participant that engages in sexual activity that has the risk of pregnancy must agree to use a double barrier method (e.g. condom and spermicide) and agree to not donate sperm during the study and for at least 90 days after the last dose of the study medication.

  8. Be able to comply with protocol requirements, rules and regulations of the study site, and be likely to complete all the study treatments.

Exclusion criteria

Exclusion Criteria:

  1. Have a current or past history of seizure disorder, including alcohol- or stimulant-related seizure, febrile seizure, or significant family history of idiopathic seizure disorder.
  2. Have any previous medically adverse reaction to cocaine, including loss of consciousness, chest pain, paranoid reaction or seizure.
  3. Have findings in the opinion of an investigator based on the MINI (version 7.0) neuropsychiatric interview.
  4. Be pregnant or lactating.
  5. Have a sitting systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg and heart rate > 100 beats per minute at screening and clinic intake.
  6. Have a history of liver disease or current elevation of liver function test (LFT) values as follows:

    • (AST) >2x the
    • alanine aminotransferase (ALT) >2 × the upper limit of normal.
  7. Have a history of renal disease or current renal function test values as follows:

    • blood urea nitrogen (BUN) >2× ULN, or
    • creatinine >1.5 mg/dL.
  8. Blood donation (excluding plasma donation) of approximately 500 mL within 56 days prior to screening.
  9. Plasma donation within 7 days prior to screening.
  10. Treatment with an drug within 30 days or 5 times the half-life (whichever is longer) prior to screening.
  11. Have consumed grapefruit or other foods that inhibit or induce within 7 days of Study Day 1.
  12. Have any clinically significant finding on medical history, physical examination, clinical laboratory test, vital signs or ECGs that contraindicate participation in the study.
  13. Have a history of suicide attempts or current or recent evidence of suicidal ideation in the past 12 months based on the Columbia-Suicide Severity Rating Scale.
  14. Have a positive urine drug screen upon clinic intake (Day -3) for any of the following drugs: alcohol, amphetamine/methamphetamine, barbiturates, benzodiazepines, buprenorphine, cocaine, fentanyl, 3,4 methylenedioxymethamphetamine (MDMA), methadone, phencyclidine/phenylcyclohexyl piperidine (PCP), propoxyphene, and opioids (e.g., codeine, heroin, morphine, oxycodone, etc.).
  15. Have used any prescription drugs within 14 days of clinic intake or non-prescription drugs or herbal remedies within 7 days of clinic intake.
  16. Be unable to distinguish between a 20 mg and 40 mg dose of cocaine i.v. based on the high effects VAS at either the 5 or 10 minute time point during the screening infusion.
  17. Have a positive serology for surface antigen (HBsAg), antibody (HCVab), or (HIV).
  18. Have positive results for a coronavirus disease 2019 (COVID-19) test performed after screening is complete and participant is confirmed, but prior to admission.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    STP7 (mavoglurant) modified release film-coated tablet

    Participants will take STP7 (mavoglurant) twice a day (BID) from Days 3 to 9 according to the following dosing schedule: * Day 3: 50 mg BID; * Day 4: 100 mg BID; * Days 5-9: 200 mg BID, * Day 10: 200 mg only the morning dose. Morning STP7 (mavoglurant) doses must be taken within 30 minutes of beginning a meal.

    Drug: STP7 (mavoglurant) · Drug: Cocaine Hydrochloride

  • Placebo comparator
    Placebo

    Participants will take matched placebo twice a day (BID) from Days 3 to 9 and only the morning dose on Day 10. Morning Placebo must be taken within 30 minutes of beginning a meal.

    Drug: Placebo · Drug: Cocaine Hydrochloride

Interventions

  • DrugMavoglurantStudies of MavoglurantMavoglurant pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    STP7 (mavoglurant) twice a day (BID) from Days 3 to 9 according to the following dosing schedule: Day 3: 50 mg BID; Day 4: 100 mg BID; Days 5-9: 200 mg BID, and will take only the morning dose of STP7 (200 mg) on Day 10.

    Also known as: AFQ056

  • DrugPlacebo

    Placebo twice a day (BID) from Days 3 to 9, and will take only the morning dose of Placebo on Day 10.

  • DrugCocaineStudies of CocaineCocaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will undergo cocaine/saline i.v. challenge sessions according to the schedule and doses: * Screening (Session 1, Day -2): 20 mg cocaine, followed by a saline infusion, followed by 40 mg cocaine * Baseline (Session 2, Day 1): saline or 20 mg cocaine followed by either 20 mg cocaine or saline. * Baseline (Session 3, Day 2): saline or 40 mg cocaine followed by either 40 mg cocaine or saline. * Treatment (Session 4, Day 9): saline or 20 mg cocaine followed by either 20 mg cocaine or saline. * Treatment (Session 5, Day 10): saline or 40 mg cocaine followed by either 40 mg cocaine or saline.

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events.

    Any events spontaneously reported by the participant or observed by the investigative staff will also be recorded.

    Time frame: On day -2, day -1, day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8, day 9, day10, day 11, day 12 and the follow-up (window from day 19 to day 26).

  2. Heart Rate response following the STP7 treatment with the cocaine infusion.

    Change of the Heart Rate.

    Time frame: Collected at day -2 at the time points (relative to the first infusion of the day): -30, - 15, 5, 10, 15, 20, 25, 30, 45, 55, 65, 70, 75, 80, 85, 90, 105, 115, 125, 130, 135, 140, 145, 150, 165, 180, 210, 240, 270, 300, 330 and 360 minutes

  3. Heart Rate response following the STP7 treatment with the cocaine infusion.

    Change of the Heart Rate.

    Time frame: Collected at day 1, day 2, day 9 and day 10 at the time points (relative to the first infusion of the day): -30, -15, 5, 10, 15, 20, 25, 30, 45, 55, 65, 70, 75, 80, 85, 90, 105, 120, 150, 180, 210, 240, 270 and 300 minutes

  4. Blood Pressure (diastolic) response following the STP7 treatment with the cocaine infusion .

    Change of the diastolic Blood Pressure.

    Time frame: Collected at day -2 at the time points (relative to the first infusion of the day): -30, - 15, 5, 10, 15, 20, 25, 30, 45, 55, 65, 70, 75, 80, 85, 90, 105, 115, 125, 130, 135, 140, 145, 150, 165, 180, 210, 240, 270, 300, 330 and 360 minutes

  5. Blood Pressure (diastolic) response following the STP7 treatment with the cocaine infusion.

    Change of the diastolic Blood Pressure.

    Time frame: Collected at day 1, day 2, day 9 and day 10 at the time points (relative to the first infusion of the day): -30, -15, 5, 10, 15, 20, 25, 30, 45, 55, 65, 70, 75, 80, 85, 90, 105, 120, 150, 180, 210, 240, 270 and 300 minutes

  6. Blood Pressure (systolic) response following the STP7 treatment with the cocaine infusion.

    Change of the systolic Blood Pressure.

    Time frame: Collected at day -2 at the time points (relative to the first infusion of the day): -30, - 15, 5, 10, 15, 20, 25, 30, 45, 55, 65, 70, 75, 80, 85, 90, 105, 115, 125, 130, 135, 140, 145, 150, 165, 180, 210, 240, 270, 300, 330 and 360 minutes

  7. Blood Pressure (systolic) response following the STP7 treatment with the cocaine infusion.

    Change of the systolic Blood Pressure.

    Time frame: Collected at day 1, day 2, day 9 and day 10 at the time points (relative to the first infusion of the day): -30, -15, 5, 10, 15, 20, 25, 30, 45, 55, 65, 70, 75, 80, 85, 90, 105, 120, 150, 180, 210, 240, 270 and 300 minutes

  8. ECG changes (HR) following the STP7 treatment with the cocaine infusion.

    Changes in ECG (HR) following STP7 treatment with the cocaine infusion at screening.

    Time frame: As collected at day -2 at -10 minutes and at 5, 10, 15, 30, 45, 65, 70, 75, 90, 105, 125, 130, 135, 150, 165, 180 and 360 minutes after the first infusion.

  9. ECG changes (RR) following the STP7 treatment with the cocaine infusion.

    Changes in ECG (RR) following STP7 treatment with the cocaine infusion at screening.

    Time frame: As collected at day -2 at -10 minutes and at 5, 10, 15, 30, 45, 65, 70, 75, 90, 105, 125, 130, 135, 150, 165, 180 and 360 minutes after the first infusion.

  10. ECG changes (PR) following the STP7 treatment with the cocaine infusion.

    Changes in ECG (PR) following STP7 treatment with the cocaine infusion at screening.

    Time frame: As collected at day -2 at -10 minutes and at 5, 10, 15, 30, 45, 65, 70, 75, 90, 105, 125, 130, 135, 150, 165, 180 and 360 minutes after the first infusion.

  11. ECG changes (QRS) following the STP7 treatment with the cocaine infusion.

    Changes in ECG (QRS) following STP7 treatment with the cocaine infusion at screening.

    Time frame: As collected at day -2 at -10 minutes and at 5, 10, 15, 30, 45, 65, 70, 75, 90, 105, 125, 130, 135, 150, 165, 180 and 360 minutes after the first infusion.

  12. ECG changes (QT) following the STP7 treatment with the cocaine infusion.

    Changes in ECG (QT) following STP7 treatment with the cocaine infusion at screening.

    Time frame: As collected at day -2 at -10 minutes and at 5, 10, 15, 30, 45, 65, 70, 75, 90, 105, 125, 130, 135, 150, 165, 180 and 360 minutes after the first infusion.

  13. ECG changes (HR) following the STP7 treatment with the cocaine infusion.

    Changes in ECG (HR) following STP7 treatment with the cocaine infusion (baseline and treatment period).

    Time frame: As collected at day 1, day 2, day 9 and day 10 at -10 minutes and at 5, 10, 15, 30, 45, 65, 70, 75, 90, 120, 150, 180 and 300 minutes after the first infusion.

  14. ECG changes (RR) following the STP7 treatment with the cocaine infusion.

    Changes in ECG (RR) following STP7 treatment with the cocaine infusion (baseline and treatment period).

    Time frame: As collected at day 1, day 2, day 9 and day 10 at -10 minutes and at 5, 10, 15, 30, 45, 65, 70, 75, 90, 120, 150, 180 and 300 minutes after the first infusion.

  15. ECG changes (PR) following the STP7 treatment with the cocaine infusion.

    Changes in ECG (PR) following STP7 treatment with the cocaine infusion (baseline and treatment period).

    Time frame: As collected at day 1, day 2, day 9 and day 10 at -10 minutes and at 5, 10, 15, 30, 45, 65, 70, 75, 90, 120, 150, 180 and 300 minutes after the first infusion.

  16. ECG changes (QRS) following the STP7 treatment with the cocaine infusion.

    Changes in ECG (QRS) following STP7 treatment with the cocaine infusion (baseline and treatment period).

    Time frame: As collected at day 1, day 2, day 9 and day 10 at -10 minutes and at 5, 10, 15, 30, 45, 65, 70, 75, 90, 120, 150, 180 and 300 minutes after the first infusion.

  17. ECG changes (QT) following the STP7 treatment with the cocaine infusion.

    Changes in ECG (QT) following STP7 treatment with the cocaine infusion (baseline and treatment period).

    Time frame: As collected at day 1, day 2, day 9 and day 10 at -10 minutes and at 5, 10, 15, 30, 45, 65, 70, 75, 90, 120, 150, 180 and 300 minutes after the first infusion.

Secondary outcomes

  1. Pharmacokinetics: Maximum Plasma Concentration [Cmax] of cocaine.

    Plasma concentration-time profiles of cocaine.

    Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.

  2. Pharmacokinetics: Maximum Plasma Concentration [Cmax] of benzoylecgonine.

    Plasma concentration-time profiles of benzoylecgonine.

    Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.

  3. Pharmacokinetics: Maximum Plasma Concentration [Cmax] of STP7.

    Plasma concentration-time profiles of STP7.

    Time frame: Day 5, day 6, day 7, day 8 and day 9: prior to the morning dose and 4 hours post-dose for each day.

  4. Pharmacokinetics: Maximum Plasma Concentration [Cmax] of STP7.

    Plasma concentration-time profiles of STP7.

    Time frame: Day 10, at pre-dose, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours post-dose.

  5. Pharmacokinetics: time to maximum plasma concentration [Tmax] of cocaine.

    Time to maximum plasma concentration of cocaine.

    Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.

  6. Pharmacokinetics: time to maximum plasma concentration [Tmax] of benzoylecgonine.

    Time to maximum plasma concentration of benzoylecgonine.

    Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.

  7. Pharmacokinetics: time to maximum plasma concentration [Tmax] of STP7.

    Time to maximum plasma concentration of STP7.

    Time frame: Day 5, day 6, day 7, day 8 and day 9: prior to the morning dose and 4 hours post-dose for each day.

  8. Pharmacokinetics: time to maximum plasma concentration [Tmax] of STP7.

    Time to maximum plasma concentration of STP7.

    Time frame: Day 10, at pre-dose, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours post-dose.

  9. Pharmacokinetics: area under the concentration-time curve from time 0 to time t of cocaine.

    Area under the concentration-time curve from time 0 to time t (AUC0-t) of cocaine.

    Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.

  10. Pharmacokinetics: area under the concentration-time curve from time 0 to time t of benzoylecgonine.

    Area under the concentration-time curve from time 0 to time t (AUC0-t) of benzoylecgonine.

    Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.

  11. Pharmacokinetics: area under the concentration-time curve from time 0 to time of STP7.

    Area under the concentration-time curve from time 0 to time t (AUC0-t) of STP7.

    Time frame: Day 5, day 6, day 7, day 8 and day 9: prior to the morning dose and 4 hours post-dose for each day.

  12. Pharmacokinetics: area under the concentration-time curve from time 0 to time of STP7.

    Area under the concentration-time curve from time 0 to time t (AUC0-t) of STP7.

    Time frame: Day 10, at pre-dose, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours post-dose.

  13. Pharmacokinetics: area under the concentration-time curve from time 0 to 12 hours post-dose of cocaine.

    Area under the concentration-time curve from time 0 to 12 hours post-dose (AUC0-12) of cocaine.

    Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.

  14. Pharmacokinetics: area under the concentration-time curve from time 0 to 12 hours post-dose of benzoylecgonine.

    Area under the concentration-time curve from time 0 to 12 hours post-dose (AUC0-12) of benzoylecgonine.

    Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.

  15. Pharmacokinetics: area under the concentration-time curve from time 0 to 12 hours post-dose of STP7.

    Area under the concentration-time curve from time 0 to 12 hours post-dose (AUC0-12) of STP7.

    Time frame: Day 5, day 6, day 7, day 8 and day 9: prior to the morning dose and 4 hours post-dose for each day.

  16. Pharmacokinetics: area under the concentration-time curve from time 0 to 12 hours post-dose of STP7.

    Area under the concentration-time curve from time 0 to 12 hours post-dose (AUC0-12) of STP7.

    Time frame: Day 10, at pre-dose, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours post-dose.

  17. Pharmacokinetics: area under the concentration-time curve from time 0 to time infinity post-dose of cocaine.

    Area under the concentration-time curve from time 0 to time infinity post-dose of cocaine.

    Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.

  18. Pharmacokinetics: area under the concentration-time curve from time 0 to time infinity post-dose of benzoylecgonine.

    Area under the concentration-time curve from time 0 to time infinity post-dose of benzoylecgonine.

    Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.

  19. Pharmacokinetics: area under the concentration-time curve from time 0 to time infinity post-dose of STP7.

    Area under the concentration-time curve from time 0 to time infinity post-dose of STP7.

    Time frame: Day 5, day 6, day 7, day 8 and day 9: prior to the morning dose and 4 hours post-dose for each day.

  20. Pharmacokinetics: area under the concentration-time curve from time 0 to time infinity post-dose of STP7.

    Area under the concentration-time curve from time 0 to time infinity post-dose of STP7.

    Time frame: Day 10, at pre-dose, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours post-dose.

  21. Pharmacokinetics: trough plasma concentration (Ctrough) of cocaine.

    Trough plasma concentration (Ctrough) of cocaine.

    Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.

  22. Pharmacokinetics: trough plasma concentration (Ctrough) of benzoylecgonine.

    Trough plasma concentration (Ctrough) of benzoylecgonine.

    Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.

  23. Pharmacokinetics: trough plasma concentration (Ctrough) of STP7.

    Trough plasma concentration (Ctrough) of STP7.

    Time frame: Day 5, day 6, day 7, day 8 and day 9: prior to the morning dose and 4 hours post-dose for each day.

  24. Pharmacokinetics: trough plasma concentration (Ctrough) of STP7.

    Trough plasma concentration (Ctrough) of STP7.

    Time frame: Day 10, at pre-dose, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours post-dose.

  25. Pharmacokinetics: terminal rate constant of cocaine.

    Terminal rate constant of cocaine.

    Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.

  26. Pharmacokinetics: terminal rate constant of benzoylecgonine.

    Terminal rate constant of benzoylecgonine.

    Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.

  27. Pharmacokinetics: terminal rate constant of STP7.

    Terminal rate constant of STP7.

    Time frame: Day 5, day 6, day 7, day 8 and day 9: prior to the morning dose and 4 hours post-dose for each day.

  28. Pharmacokinetics: terminal rate constant of STP7.

    Terminal rate constant of STP7.

    Time frame: Day 10, at pre-dose, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours post-dose.

  29. Pharmacokinetics: half-life of cocaine.

    Half-life (t1/2) of cocaine

    Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.

  30. Pharmacokinetics: half-life of benzoylecgonine.

    Half-life (t1/2) of benzoylecgonine.

    Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.

  31. Pharmacokinetics: half-life of STP7.

    Half-life (t1/2) of STP7.

    Time frame: Day 5, day 6, day 7, day 8 and day 9: prior to the morning dose and 4 hours post-dose for each day.

  32. Pharmacokinetics: half-life of STP7.

    Half-life (t1/2) of STP7.

    Time frame: Day 10, at pre-dose, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours post-dose.

  33. Pharmacokinetics: clearance of cocaine.

    Clearance (CL) of cocaine.

    Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.

  34. Pharmacokinetics: clearance of benzoylecgonine.

    Clearance (CL) of benzoylecgonine.

    Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.

  35. Pharmacokinetics: clearance of STP7.

    Clearance (CL) of STP7.

    Time frame: Day 5, day 6, day 7, day 8 and day 9: prior to the morning dose and 4 hours post-dose for each day.

  36. Pharmacokinetics: clearance of STP7.

    Clearance (CL) of STP7.

    Time frame: Day 10, at pre-dose, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours post-dose.

  37. Pharmacokinetics: Clearance from plasma after oral administration of cocaine.

    Clearance from plasma after oral administration (CL/F) of cocaine.

    Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.

  38. Pharmacokinetics: Clearance of benzoylecgonine from plasma after oral administration (CL/F) of cocaine.

    Clearance of benzoylecgonine from plasma after oral administration (CL/F) of cocaine.

    Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.

  39. Pharmacokinetics: Clearance from plasma after oral administration (CL/F) of STP7.

    Clearance from plasma after oral administration (CL/F) of STP7.

    Time frame: Day 5, day 6, day 7, day 8 and day 9: prior to the morning dose and 4 hours post-dose for each day.

  40. Pharmacokinetics: Clearance from plasma after oral administration (CL/F) of STP7.

    Clearance from plasma after oral administration (CL/F) of STP7.

    Time frame: Day 10, at pre-dose, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours post-dose.

  41. Visual evaluation of the STP7 on the subjective effects of cocaine at screening

    To evaluate whether STP7 treatment alters the subjective effects of cocaine measured by Visual Analog Scales (VAS).

    Time frame: Day -2: 30 minutes prior to cocaine infusion and at 5, 10, 15, 30, 45, 55, 65, 70, 75, 90, 105, 115, 125, 130, 135, 150, 165 and 180 minutes after the first infusion.

  42. Visual evaluation of the STP7 on the subjective effects of cocaine at baseline and during treatment

    To evaluate whether STP7 treatment alters the subjective effects of cocaine measured by Visual Analog Scales (VAS).

    Time frame: Day 1, day 2, day 9 and day 10: at -30, 5, 10, 15, 30, 45, 55, 65, 70, 75, 90, 105 and 120 minutes after the first infusion.

  43. Craving evaluation of the STP7 on the subjective effects of cocaine.

    To evaluate whether STP7 treatment alters the subjective effects of cocaine on craving measured by the score of the Brief Substance Craving Scale (BSCS).

    Time frame: Day -2, day 1, day 2, day 9 and day 10: at pre-infusion and 125 minutes after the start of the cocaine infusion.

07

Study locations

1 site
  • Altasciences Clinical Kansas
    Overland Park, Kansas 66212, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2024 to primary completion in Oct 2024, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2024
First posted
Feb 22, 2024
StartActual
Apr 15, 2024
Primary completionActual
Oct 7, 2024
CompletionActual
Oct 7, 2024
Results delay requested
Oct 3, 2025
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06273540
Lead sponsor
Stalicla SA
Responsible party
Sponsor
First posted
Feb 22, 2024
Start date
Apr 15, 2024
Primary completion
Oct 7, 2024
Completion
Oct 7, 2024
Last update
Nov 18, 2026

Study contacts

Debra Kelsh, MD
principal investigator · Altasciences Company Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Mavoglurant · Cocaine

Start the discussion